Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
AMYRIS, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.001 USD | 0.00% | -90.00% | -99.93% | |
| Dec. 05 | THG buys skincare brand Biossance for USD20 million | AN |
| Dec. 05 | E-commerce Retailer THG to Buy Skincare Brand Biossance | MT |
Financials (USD)
| Sales 2023 * | 488M | Sales 2024 * | 530M | Capitalization | 372K |
|---|---|---|---|---|---|
| Net income 2023 * | -335M | Net income 2024 * | -278M | EV / Sales 2023 * | 0,00x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0,00x |
| P/E ratio 2023 * | 0,00x | P/E ratio 2024 * | 0,00x | Employees | 1,598 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 94.16% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +66.67% | ||
| 1 week | -90.00% | ||
| Current month | -92.00% | ||
| 3 months | -97.77% | ||
| 6 months | -99.88% | ||
| Current year | -99.93% |
1 week
0.00
0.02
1 month
0.000.02
Current year
0.001.92
1 year
0.002.30
3 years
0.0023.42
5 years
0.0023.42
10 years
0.0091.65
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2020 | |
Sunil Chandran
CTO | Chief Tech/Sci/R&D Officer | - | 2005 |
Eduardo Alvarez
COO | Chief Operating Officer | 59 | 2017 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Mills
BRD | Director/Board Member | 67 | 2018 |
John Doerr
BRD | Director/Board Member | 71 | 2006 |
Geoffrey Duyk
CHM | Chairman | 63 | 2012 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 660 M€ | +3.38% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 0.001 | 0.00% | 132 619 |
| 23-12-05 | 0.001 | +66.67% | 1,885,836 |
| 23-12-04 | 0.0006 | -95.20% | 962,553 |
| 23-12-01 | 0.0125 | 0.00% | 1,949,136 |
| 23-11-30 | 0.0125 | +25.00% | 1,053,061 |
Delayed Quote OTC Markets, December 05, 2023 at 03:59 pm EST
More quotes
Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Company's sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.
Sector
Specialty Chemicals
Calendar
2024-03-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -99.93% | 372 069 $ | |
| +30.53% | 54 177 M $ | |
| +7.62% | 43 730 M $ | |
| +16.20% | 34 706 M $ | |
| -0.08% | 16 715 M $ | |
| +3.30% | 15 840 M $ | |
| -47.77% | 13 291 M $ | |
| +35.75% | 9 914 M $ | |
| -2.84% | 8 764 M $ | |
| -41.70% | 8 001 M $ |
